



Neuroplasticity and neuromodulation at different scales

June 6-7, 2019. Antwerp, Belgium.

Presenting Author:

Surname	Goossens	Name	Marie-Gabrielle	Title	Ir.
Institution	Ghent University				
Address	Ghent University Hospital - Blok B (entrance 36), Corneel Heymanslaan 10				
Postal code	9000	City	Ghent	Country	Belgium
Email	MarieGabrielle.Goossens@ugent.be	Phone	09 332 33 55		

Chemogenetic suppression of spontaneous seizures in a rat model for temporal lobe epilepsy

Marie-Gabrielle Goossens¹, Emma Christiaen², Paul Boon¹, Kristl Vonck¹, Evelien Carrette¹, Jana Desloovere¹, Chris Van Den Haute³, Veerle Baekelandt³, Wytse Wadman¹, Christian Vanhove², Robrecht Raedt¹

¹ 4BRAIN (Department of Head and Skin), Ghent University, Ghent, Belgium

² MEDISIP (Department of Electronics and Information Systems), Ghent University, Ghent, Belgium

³ Research Group for Neurobiology and Gene Therapy (Department of Neurosciences), Katholieke Universiteit Leuven, Leuven, Belgium

The hippocampus is believed to play a crucial role in seizure generation in temporal lobe epilepsy (TLE), a common form of medication-resistant epilepsy. This preclinical study

evaluated chemogenetics as a potential therapy for TLE. Using this approach, excitatory neurons of the epileptic hippocampus were selectively inhibited through ligand-based activation of an inhibitory Designer Receptor Exclusively Activated by Designer Drugs (DREADD).

The intraperitoneal kainic acid rat model for TLE was used. Animals (n=6) were injected in right hippocampus with adeno-associated viral vector carrying CamKII α -hM4Di-mCherry. Two weeks after injection, rats were bilaterally implanted with depth electrodes in the dentate gyrus and CA1 region of both hippocampi. Seizure frequency before and after activating DREADDs with subclinical doses of clozapine was determined using continuous video-EEG recordings. First, EEG was monitored during a baseline period of six days. Next, single injections of different clozapine doses (0.01, 0.1 or 1 mg/kg bodyweight/24h, s.c.) and vehicle were compared. For each dose, EEG was monitored during three days of treatment. Finally, one dose was selected to evaluate an improved dosing scheme in a randomized-blind trial. EEG was monitored during a baseline period of one days, followed by one day of treatment with clozapine (0.1mg/kg bodyweight/6h) or vehicle. In all experiments, seizure frequency during baseline recordings was used to normalize the data.

Clozapine-induced activation of DREADDs had a dose-dependent seizure suppressing effect. Clozapine doses of 0.01, 0.1 and 1 mg/kg resulted in a clear lag in average cumulative seizure frequency of about 2, 5 and 8 hours respectively. Repeated clozapine administration resulted in a strong suppression of epileptic seizures in all animals tested. During treatment, the average daily seizure frequency was reduced with $86\pm 7\%$ (SEM).

Clozapine-mediated activation of hM4Di DREADDs in excitatory hippocampal neurons temporary suppresses spontaneous seizures in a rat model for TLE in a dose-dependent way. Repeated clozapine administration results in a sustained suppression of epileptic seizures.